Brain Metabolic Alterations in Seropositive Autoimmune Encephalitis: An
autoimmune encephalitis
diagnostic imaging
imaging biomarkers
metabolism
positron emission tomography
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
09 Feb 2023
09 Feb 2023
Historique:
received:
03
01
2023
revised:
30
01
2023
accepted:
07
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Autoimmune encephalitis (AE) diagnosis and follow-up remain challenging. Brain We retrospectively included patients with available FDG PET and seropositive AE diagnosed in our center between 2015 and 2020. Brain PET Z-score maps (relative to age matched controls) were analyzed, considering metabolic changes significant if |Z-score| ≥ 2. Forty-six patients were included (49.4 yrs [18; 81]): 13 with GAD autoantibodies, 11 with anti-LGI1, 9 with NMDAR, 5 with CASPR2, and 8 with other antibodies. Brain PET was abnormal in 98% of patients versus 53% for MRI. The most frequent abnormalities were medial temporal lobe (MTL) and/or striatum hypermetabolism (52% and 43% respectively), cortical hypometabolism (78%), and cerebellum abnormalities (70%). LGI1 AE tended to have more frequent MTL hypermetabolism. NMDAR AE was prone to widespread cortical hypometabolism. Fewer abnormalities were observed in GAD AE. Striatum hypermetabolism was more frequent in patients treated for less than 1 month ( FDG PET could serve as an imaging biomarker for early diagnosis and follow-up in AE.
Identifiants
pubmed: 36831042
pii: biomedicines11020506
doi: 10.3390/biomedicines11020506
pmc: PMC9953044
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3847-3858
pubmed: 33677643
Front Neurol. 2019 Jan 09;9:1143
pubmed: 30687213
Clin Nucl Med. 2016 May;41(5):366-70
pubmed: 26914566
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):632-651
pubmed: 34882261
Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):
pubmed: 34006622
J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):840-8
pubmed: 25511790
Brain Behav. 2020 Mar;10(3):e01540
pubmed: 31985135
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e413
pubmed: 29159205
Ann Nucl Med. 2020 Aug;34(8):565-574
pubmed: 32578152
Diagnostics (Basel). 2020 May 29;10(6):
pubmed: 32486044
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):921-931
pubmed: 34462791
BMC Neurol. 2014 Jun 20;14:136
pubmed: 24950993
J Nucl Med. 2018 Oct;59(10):1590-1596
pubmed: 29626122
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Mar - Apr;39(2):92-95
pubmed: 31784408
Clin Nucl Med. 2015 Sep;40(9):e441-3
pubmed: 26053709
Brain. 2016 Apr;139(Pt 4):1079-93
pubmed: 26945884
Psychosomatics. 2020 Jan - Feb;61(1):39-48
pubmed: 31611047
Front Neurol. 2019 Jun 06;10:576
pubmed: 31244751
Front Immunol. 2021 May 13;12:652864
pubmed: 34054814
Int J Mol Sci. 2020 May 24;21(10):
pubmed: 32456344
J Neurol. 2013 Nov;260(11):2744-53
pubmed: 23900756
Brain Cogn. 2016 Oct;108:81-7
pubmed: 27566001
Brain. 2010 Jun;133(Pt 6):1655-67
pubmed: 20511282
Neuroradiology. 2018 Feb;60(2):189-198
pubmed: 29255919
CNS Neurosci Ther. 2021 Oct;27(10):1173-1181
pubmed: 34291554
J Nucl Med. 2017 Aug;58(8):1307-1313
pubmed: 28209905
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neurosci. 2010 Apr 28;30(17):5866-75
pubmed: 20427647
Front Neurol. 2020 Jun 05;11:418
pubmed: 32581996
Front Neurol. 2017 Sep 01;8:453
pubmed: 28919879
Brain. 2022 Nov 21;145(11):3843-3858
pubmed: 35727946
Ther Adv Neurol Disord. 2021 Feb 24;14:1756286421995635
pubmed: 33717212
PLoS One. 2020 Jan 17;15(1):e0227906
pubmed: 31951636
Cell. 2022 Jul 7;185(14):2469-2477.e13
pubmed: 35803245
Neurol Neuroimmunol Neuroinflamm. 2021 Dec 13;9(1):
pubmed: 34903638